Morocco, the second biggest pharmaceutical market in Africa after South Africa, has since the 2006 approval of a strengthened liberalization policy attracted private financing and investments.
Resverlogix is holding talks with the Ministry of Health of the Kingdom of Morocco to conduct Phase II clinical trials of its drug, apabetalone (RVX-208), for Covid-19.